Feb 5, 2024 · Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. J Neurosci. 2016 Dec 7;36(49):12425-12435. PubMed. Gärtner U, Janke C, Holzer M, Vanmechelen E, Arendt T. Postmortem changes in the phosphorylation state of tau-protein in the rat brain.

Jan 8, 2025 · The antibody is intended to bind extracellular tau, prevent cell-to-cell propagation of pathogenic species, and mediate clearance by microglia. Some data indicate that mid-region antibodies more potently interfere with the propagation of pathogenic, aggregated tau than do N-terminally targeted anti-tau antibodies, which have shown no efficacy ...

Feb 6, 2024 · The MC-1 epitope was defined by deletion mapping using recombinant tau protein, and it was found that two discontinuous regions are required for antibody binding—amino acids 7-9 near the N terminus and a sequence between amino acids 313 and 322 in the third repeat domain—and that the epitope is formed by intramolecular interactions (Jicha ...

Feb 18, 2025 · A tau–fluorescence resonance energy transfer (FRET) assay developed by Revvity, Inc, a biotech company based in Waltham, Massachusetts. In this version, a tau antibody is attached to either a fluorescent donor or acceptor. FRET only occurs when both are close, and because tau monomers can only bind one antibody, they go undetected.

Mar 27, 2021 · Meanwhile, CSF total tau, as measured by an Elecsys assay that recognizes a mid-domain region, and phosphorylated tau dropped at all doses of drug compared to the placebo groups. This was consistent with mouse data, and demonstrates that the antibody altered tau processing, Wildsmith said. Lower CSF tau is associated with less pathology in AD.

Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997 Apr 15;48(2):128-32. PubMed. If you know of any papers that use this antibody, please contact us at antibodies [at] alzforum [dot] org for consideration in the References section.

Sep 10, 2024 · Zagotenemab is a humanized anti-tau antibody derived from MCI-1, Peter Davies' mouse monoclonal antibody against an early pathological conformation of tau. Zagotenemab binds and neutralizes soluble tau aggregates.

May 20, 2014 · This antibody recognizes a folded conformation of tau containing amino acids 2-10 and 312-342. We have used it successfully to detect misfolded tau in mouse models of tauopathy using array tomography, a relatively new imaging technique (Kopeikina et al., 2013). References:

Apr 11, 2024 · Curious if the antibody has effects beyond tau, the researchers measured the hippocampal proteome from 10-month-old mice using mass spectrometry. From about 10,000 proteins, they found 2,146 up- or downregulated in PS19 mice compared to non-transgenic controls, most of which were involved in neurotransmission and synaptic signaling.

Jun 28, 2024 · This humanized IgG1 monoclonal antibody binds the proline-rich domain of tau, on the rationale that such antibodies will more potently interfere with cell-to-cell propagation of pathogenic, aggregated tau than do antibodies targeting tau's N-terminus. It has high affinity for tau phosphorylated at residue 217.